VESALIUS-CV

Ask MedXY AI

Latest news

Tag

Cardiologycardiovascular riskEvolocumab

Sustained Cardiovascular Protection With Evolocumab in Patients Without Prior MI or Stroke: Insights From the VESALIUS-CV Trial

By MedXY|Aug 29, 2026

Evolocumab significantly reduces first and subsequent major adverse cardiovascular events in high-risk patients without prior myocardial infarction or stroke, affirming the benefit of intensive LDL-C lowering for cumulative cardiovascular r

Cardiologycoronary preventionEvolocumab

Higher Lipoprotein(a) Marks Greater Coronary Risk Without Prior MI or Stroke, While Evolocumab Delivers Similar Relative Benefit and Larger Absolute Gains

By MedXY|May 25, 2026

In VESALIUS-CV, elevated baseline Lp(a) independently predicted major coronary events, especially MI, in patients without prior MI or stroke. Evolocumab reduced relative risk similarly across Lp(a) levels, with numerically greater absolute